Global

Sandoz has put a date on its golden decade for biosimilars. The Bio100 plan targets more than 100 biosimilars by 2040, about 80% coverage of biosimilar-addressable LoE value from 2035, and a doubling of 2025 net sales. #SyenzaNews #MarketAccess #Biosimilars #ValueCreation

Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding. #SyenzaNews #MarketAccess #GlobalHealth

An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF

Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica

Trump's Most Favored Nation drug pricing policy is already delaying new medicine launches in Europe. Brussels journalist Christoffer Frendesen unpacks the silence, the data, and why it may outlast the Trump presidency. #SyenzaNews #MarketAccess #DrugPricing

FDA has authorized Stryker SportSuite Vision, the first surgical application built for Apple Vision Pro. The De Novo clearance is narrow: hip arthroscopy display, used alongside standard monitors. #SyenzaNews #DigitalHealth #MedTech #FDA #AppleVisionPro

Novartis' oral BTK inhibitor remibrutinib met its primary endpoint in the Phase III REMODEL-1 and REMODEL-2 trials, cutting annualized relapse rates versus teriflunomide in relapsing multiple sclerosis. #SyenzaNews #MultipleSclerosis #MarketAccess #Neurology

Cipla has licensed Sino Biopharm's HER2 biparatopic ADC TQB2102 for India, South Africa and five other emerging markets. The deal caps at USD 123 million plus double-digit royalties, with access to HER2-low breast cancer as the core case. #SyenzaNews #Oncology #MarketAccess #DrugDevelopment

Insurers are spending billions on breakthrough medicines, but the tests that decide who gets them are still an afterthought. Kathryn Phillips lays out four reforms to link drug and diagnostic policy pathways. #SyenzaNews #diagnostics #healtheconomics #MarketAccess

A new benchmark in npj Digital Medicine finds frontier AI models at near-perfect accuracy on German medical licensing exams, yet image questions still cut their scores far more than for students. #SyenzaNews #AIinHealthcare #DigitalHealth

Finland, UNRISD and the WHO asked what the Economics of Health for All strategy means for the next generation, from intergenerational fairness and participatory foresight to dignified access to care. #SyenzaNews #HealthEconomics #WellbeingEconomy

The HTAi 2026 Annual Meeting in Istanbul drew 780+ delegates from 64 countries to reframe HTA as a system shaper, not just an evaluator of technologies.